Home
    Disclaimer
    ← Back to MDPHP
    MDPHP molecular structure

    MDPHP Stats & Data

    Stimulant Research-chemical
    Rave Mdpv Nrg-1 Magic O-2482 monkey-dust bath_salts
    NPS DataHub
    MW281.4
    FormulaC19H23NO
    CAS850352-53-3
    IUPAC(2~{S})-1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one
    SMILESCCCC(N1CCCC1)C(=O)c1ccc2ccccc2c1
    InChIKeyDTNUPBSOODGRKW-UHFFFAOYSA-N
    Phenethylamines; Cathinones; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Amphetamine
    Psychoactive Class Stimulant
    Half-Life Unknown in humans; forensic literature notes lack of PK data. Clinical effects commonly persist beyond several hours due to redosing and sleep loss.

    Receptor Profile

    Receptor Actions

    Inhibitors
    Dopamine-norepinephrine reuptake inhibitor (NDRI)
    Dopamine reuptake inhibitor (IC50 4.1-10 nM)
    Norepinephrine reuptake inhibitor (IC50 26-80 nM)

    Effect Profile

    Curated + 107 Reports
    Empathogen 7.9

    Strong euphoria and stimulation with moderate sensory enhancement and empathy

    Empathy / Social Openness×3
    65.0
    Euphoria / Mood Elevation×2
    108.6
    Stimulation×1
    108.8
    Sensory Enhancement×1
    78.1
    Catalog Erowid
    Stimulant 8.8

    Strong stimulation, euphoria, focus, and anxiety/jitters

    Stimulation / Energy×3
    1010
    Euphoria / Mood Lift×2
    108.3
    Focus / Productivity×2
    106.9
    Anxiety / Jitters×1
    1010
    Catalog Erowid
    Based on reports from:
    Erowid Experience Reports PsychonautWiki MDPHP

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; forensic literature notes lack of PK data. Clinical effects commonly persist beyond several hours due to redosing and sleep loss.
    Addiction Potential
    Moderate-to-high; many users report strong compulsive redosing, particularly when vaporized/smoked. Fatal intoxication cases exist, including monointoxication, underscoring high misuse liability.

    Tolerance Decay

    Full tolerance 1d Half tolerance 4d Baseline ~10d

    Strong acute tolerance within a session with rapidly diminishing euphoria; inter‑session tolerance decays over several days. Data are largely anecdotal from user reports across pyrrolidinophenones; individual variability is large.

    Cross-Tolerances

    synthetic cathinones (pyrrolidinophenones)
    60% ●○○
    amphetamines
    30% ●○○

    Experience Report Analysis

    Erowid
    107 Reports
    2005–2017 Date Range
    89 With Age Data
    29 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 107 experience reports (107 Erowid)

    107 Reports
    29 Effects Detected
    10 Positive
    13 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 10

    Stimulation 57.0% 70%
    Euphoria 55.1% 70%
    Focus Enhancement 34.6% 70%
    Empathy 25.2% 70%
    Music Enhancement 20.6% 70%
    Tactile Enhancement 17.8% 70%
    Color Enhancement 12.1% 70%
    Creativity Enhancement 10.3% 70%
    Introspection 8.4% 70%
    Body High 4.7% 70%

    Adverse Effects 13

    Anxiety 49.5% 70%
    Increased Heart Rate 25.2% 70%
    Confusion 19.6% 70%
    Jaw Clenching 13.1% 70%
    Headache 12.1% 70%
    Psychosis 11.2% 70%
    Nausea 11.2% 70%
    Pupil Dilation 10.3% 70%
    Muscle Tension 9.3% 70%
    Sweating 8.4% 70%
    Motor Impairment 6.5% 70%
    Memory Suppression 2.8% 70%
    Appetite Suppression 2.8% 70%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 10.0 mg IQR: 5.0–11.0 mg n=20

    Real-World Dose Distribution

    62K Doses

    From 149 individual dose entries

    Insufflated (n=98)

    Median: 12.0mg 25th: 7.0mg 75th: 15.0mg 90th: 20.0mg
    mg/kg median: 0.117 mg/kg 75th: 0.192

    Smoked (n=6)

    Median: 10.0mg 25th: 7.75mg 75th: 10.0mg 90th: 12.5mg
    mg/kg median: 0.126 mg/kg 75th: 0.141

    Oral (n=16)

    Median: 14.5mg 25th: 10.0mg 75th: 16.25mg 90th: 25.0mg
    mg/kg median: 0.209 mg/kg 75th: 0.22

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.119 mg/kg IQR: 0.071–0.182 mg/kg n=20

    Redose Patterns

    Redosing behavior across 80 reports

    35.0% Redosed
    1.7 Avg Doses
    105m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Australia In Western Australia, MDPV has been banned under the Poisons Act 1964, having been included in Appendix A Schedule 9 of the Poisons Act 1964 as from February 11, 2012. The Director of Public Prosecutions for Western Australia announced that anyone intending to sell or supply MDPV faces a maximum $100,000 fine or 25 years in jail. Users face a $2000 fine or two years' jail. Therefore, anyone caught with MDPV can be charged with possession, selling, supplying or intent to sell or supply.
    Austria Since June 26, 2019, MDPV is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
    Belgium MDPV is a controlled substance as of March 20, 2013.
    Brazil MDPV is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.
    Bulgaria MDPV is controlled under the Narcotic Substances Control Law as of February 2011.
    Canada Canadian Health Minister Leona Aglukkaq announced on June 5, 2012, that MDPV would be listed on Schedule I of the Controlled Drugs and Substances Act, which was realized on September 26, 2012.
    Croatia MDPV is a controlled substance.
    Cyprus MDPV a Class B controlled substance, as it is covered by the cathinones catch-all clause.
    Czech Republic MDPV is a controlled substance.
    Denmark MDPV is a controlled substance.
    Estonia MDPV is a controlled substance as of November 29, 2010.
    Finland MDPV is specifically listed as a controlled substance in Finland (listed appendix IV substance as of June 28, 2010),
    France MDPV is a controlled substance as of August 2, 2012.
    Germany MDPV is controlled under Anlage II BtMG ( Narcotics Act, Schedule II ) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
    Hungary MDPV a Schedule A controlled psychotropic substance.
    Ireland MDPV is covered by the Misuse of Drugs Acts since May 11, 2010.
    Italy MDPV is a controlled substance as of December 29, 2011.
    Latvia MDPV is a controlled substance.
    Luxembourg MDPV is a controlled substance as of July 30, 2012.
    Norway MDPV is a controlled substance as of Febuary 14, 2013.
    Poland MDPV is a controlled substance.
    Slovakia MDPV a Schedule I controlled psychotropic substance as of March 1, 2011.
    Slovenia MDPV is a controlled substance.
    Sweden MDPV is a controlled substance. In Sweden a 33-year-old man has been sentenced to six years in prison by an appellate court, Hovrätt, for possession of 250 grams of MDPV that had been acquired prior to criminalization.
    Switzerland MDPV is a controlled substance specifically named under Verzeichnis D.
    Turkey MDPV is a controlled substance.
    United Kingdom In the UK, following the ACMD's report on substituted cathinone derivatives, MDPV is a Class B drug under The Misuse of Drugs Act 1971 (Amendment) Order 2010, making it illegal to sell, buy, or possess without a license.
    United States In the United States, MDPV is a DEA federally scheduled drug. On October 21, 2011, the DEA issued a temporary one-year ban on MDPV, classifying it as a schedule I substance. Schedule I status is reserved for substances with a high potential for abuse, no currently accepted use for treatment in the United States and a lack of accepted safety standards for use under medical supervision. Before the federal ban was announced, MDPV was already banned in Louisiana and Florida. On March 24, 2011, Kentucky passed bill HB 121, which makes MDPV, as well as three other cathinones, controlled substances in the state. It also makes it a Class A misdemeanor to sell the drug, and a Class B misdemeanor to possess it. MDPV is banned in New Jersey under Pamela's Law. The law is named after Pamela Schmidt, a Rutgers University student who was murdered in March 2011 by an alleged user of MDPV. A toxicology report later found no "bath salts" in his system. On May 5, 2011, Tennessee Governor Bill Haslam signed a law making it a crime "to knowingly produce, manufacture, distribute, sell, offer for sale or possess with intent to produce, manufacture, distribute, sell, or offer for sale" any product containing MDPV. On July 6, 2011, the governor of Maine signed a bill establishing fines for possession and penalties for trafficking of MDPV. On October 17, 2011, an Ohio law banning synthetic drugs took effect barring selling and/or possession of "any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers", listing ephedrine and pyrovalerone. It also specifically includes MDPV. Four days after this Ohio law was passed, the DEA's national emergency ban was implemented. On December 8, 2011, under the Synthetic Drug Control Act, the US House of Representatives voted to ban MDPV and a variety of other synthetic drugs that had been legally sold in stores.

    Harm Reduction

    drugs.wiki

    • Multiple forensic case reports confirm that MDPHP alone can be lethal and often presents with pulmonary edema and severe sympathomimetic signs; reported post‑mortem blood levels vary widely, reflecting unknown human pharmacokinetics and possible multi‑timepoint use. Oral ingestion has been inferred around 60–90 minutes before collapse in at least one case. • PK in humans is not characterized; forensic authors explicitly note that no formal ADME data are available. Effects often outlast expected elimination due to redosing and sleep loss. • Vaporizing freebase produces an almost instantaneous rush, very short peak, and intense craving to redose every minutes; multi‑hour binges with psychosis and severe sleep deprivation are repeatedly reported. • Oral dosing is generally the least compulsive; spacing redoses by several hours markedly reduces adverse effects and next‑day insomnia. • Prominent adverse effects include tachycardia, hypertension, vasoconstriction with cold extremities, jaw tension, sweating, anxiety/paranoia, and insomnia; high doses and sleep deprivation increase risk of stimulant psychosis. • Non‑selective beta‑blockers can theoretically worsen stimulant‑induced vasoconstriction; for agitation/overstimulation, first‑line harm‑reduction is rest in a cool environment and anxiolytics (e.g., prescribed benzodiazepines) rather than self‑medicating with beta‑blockers. • Avoid combinations that lower seizure threshold (e.g., tramadol, high‑dose bupropion). • Mislabeling within the cathinone market is common (e.g., α‑PVP/MDPPP sold as 3‑MMC); reagent/drug‑checking is advised and test a tiny dose first even if it looks familiar. • Freebase/smoking leaves a persistent amine‑like odor that can cling to hair/clothes and indoor spaces; ensure ventilation and consider routes that reduce neighborhood exposure and binge risk. • For nasal use, crush finely, use personal equipment, pre/post saline, and rotate nostrils to reduce tissue injury. • Maintain hydration and electrolytes, avoid overheating and prolonged exertion, and protect sleep; many severe reactions follow continuous wakefulness rather than a single dose.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to MDPHP